Zylox Tonbridge (2190 HK): Domestic Holds, International Stellar in 1H26, Pipeline and Launches Key
Zylox TB posted 31% YoY higher sales due to growth witnessed across segments. International business was robust. Global growth prospects will...
93 Views
China Healthcare Weekly (Mar.17) - VBP on ICL/Sports Medicine, New Payment System, Time to Long CXO?
National VBP on ICL/sports medicine and other fields is coming.It's expected to see the emergence of high-price-oriented payment system for...
551 Views
China Healthcare Weekly (Dec.16) - ICU Expansion, Abnormal Medical Demand, Dying Chapter 18A of HKEX
Investor should treat ICU expansion rationally due to staff shortage. Demand during COVID was abnormal, which may have natural growth in 23H2. IPO...
661 Views
Primer: Acotec Scientific Holdings (6669 HK) - Oct 2025
Acotec Scientific is a leading domestic player in China's drug-coated balloon (DCB) market, poised to benefit from the growing prevalence of...
229 Views
Skyworth Group (751 HK)'s Latest Partial Buyback. Thoughts On Proration
If the price gets (even) closer to the tender price, assuming investors want to come out short and expect no surprise shift in proration, it's...
608 Views